Losartan Formulation



Version **Revision Date:** SDS Number: Date of last issue: 26.09.2023 06.04.2024 19366-00023 Date of first issue: 07.10.2014 5.0

Section 1: Identification

Product identifier Losartan Formulation

Recommended use of the chemical and restrictions on use

Recommended use Pharmaceutical Restrictions on use Not applicable

Manufacturer or supplier's details

Company : Organon & Co.

30 Hudson Street, 33nd floor Address

Jersey City, New Jersey, U.S.A 07302

Telephone +1-551-430-6000

Emergency telephone number: +1-215-631-6999

E-mail address EHSSTEWARD@organon.com

Section 2: Hazard identification

Classification of the substance or mixture

Acute toxicity (Oral) Category 4

Serious eye damage/eye irri-

tation

Category 1

Skin sensitisation Category 1

Category 1B Reproductive toxicity

Effects on or via lactation

repeated exposure (Oral)

Specific target organ toxicity - : Category 2 (Blood, Cardio-vascular system, Stomach, Kidney)

GHS Label elements, including precautionary statements

Hazard pictograms



Signal word Danger

lazard statements H302 Harmful if swallowed.

H317 May cause an allergic skin reaction.

Losartan Formulation



Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.0 06.04.2024 19366-00023 Date of first issue: 07.10.2014

H318 Causes serious eye damage.

H360D May damage the unborn child.

H362 May cause harm to breast-fed children.

H373 May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated ex-

posure if swallowed.

Precautionary statements

Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P260 Do not breathe dust.

P263 Avoid contact during pregnancy and while nursing.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P272 Contaminated work clothing should not be allowed out of the workplace.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON

CENTER/ doctor if you feel unwell. Rinse mouth.

P302 + P352 IF ON SKIN: Wash with plenty of water.

P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.

P308 + P313 IF exposed or concerned: Get medical advice/attention.

P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name CAS-No. Concentration (% w/w)	Chemical name	CAS-No.	Concentration (% w/w)
---	---------------	---------	-----------------------



Losartan Formulation



Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.0 06.04.2024 19366-00023 Date of first issue: 07.10.2014

Cellulose	9004-34-6	>= 30 -< 50
Losartan	124750-99-8	>= 30 -< 50
Starch	9005-25-8	>= 10 -< 20

Section 4: First-aid measures

Description of necessary first-aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention immediately.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed

Risks : Harmful if swallowed.

May cause an allergic skin reaction. Causes serious eye damage. May damage the unborn child.

May cause harm to breast-fed children.

May cause damage to organs through prolonged or repeated

exposure if swallowed.

Contact with dust can cause mechanical irritation or drying of

the skin.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam

Losartan Formulation



Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.0 06.04.2024 19366-00023 Date of first issue: 07.10.2014

Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

. None known.

Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Chlorine compounds Nitrogen oxides (NOx)

Special protective actions for fire-fighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

Losartan Formulation



Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.0 06.04.2024 19366-00023 Date of first issue: 07.10.2014

certain local or national requirements.

Section 7: Handling and storage

Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Avoid contact during pregnancy and while nursing.

Do not get on skin or clothing.

Do not breathe dust. Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke.

Contaminated work clothing should not be allowed out of the

workplace.

Wash contaminated clothing before re-use.

Conditions for safe storage, including any incompatibilities

Conditions for safe storage : Keep in properly labelled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Section 8: Exposure controls/personal protection

Control parameters

Occupational Exposure Limits





Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.0 06.04.2024 19366-00023 Date of first issue: 07.10.2014

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	PEL (long term)	10 mg/m3	SG OEL
		TWA	10 mg/m3	ACGIH
Losartan	124750-99-8	TWA	100 μg/m3 (OEB 2)	Internal
Starch	9005-25-8	PEL (long term)	10 mg/m3	SG OEL
		TWA	10 mg/m3	ACGIH

Appropriate engineering control measures

Minimize workplace exposure concentrations. Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the

work area (i.e., there is no leakage from the equipment). If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Individual protection measures, such as personal protective equipment (PPE)

Eye/face protection : Wear the following personal protective equipment:

Chemical resistant goggles must be worn. If splashes are likely to occur, wear:

Face-shield

Skin protection : Select appropriate protective clothing based on chemical

resistance data and an assessment of the local exposure

potential.

Skin contact must be avoided by using impervious protective

clothing (gloves, aprons, boots, etc).

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type
Hand protection

: Particulates type

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending

on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the

end of workday.

Section 9: Physical and chemical properties

Appearance : powder

Losartan Formulation



Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.0 06.04.2024 19366-00023 Date of first issue: 07.10.2014

Colour : White to light yellow

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : 1 g/cm³

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Losartan Formulation



Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.0 06.04.2024 19366-00023 Date of first issue: 07.10.2014

Molecular weight : No data available

Minimum ignition energy : > 300 mJ

Particle characteristics

Particle size : No data available

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition : No h

products

No hazardous decomposition products are known.

Section 11: Toxicological information

Information on likely routes of:

exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,502 mg/kg

Method: Calculation method

Components:

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Losartan:

Acute oral toxicity : LD50 (Mouse): 1,257 - 1,590 mg/kg



™ORGANON

Losartan Formulation

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.0 06.04.2024 19366-00023 Date of first issue: 07.10.2014

LDLo (Rat): 200 mg/kg

LDLo (Mouse): 400 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Losartan:

Species : Rabbit

Result : Mild skin irritation

Serious eye damage/eye irritation

Causes serious eye damage.

Components:

Losartan:

Species : Rabbit

Result : Severe irritation

Starch:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

May cause an allergic skin reaction.

Respiratory sensitisation

Not classified based on available information.

Components:

Losartan:

Test Type : Maximisation Test Exposure routes : Skin contact Species : Guinea pig

Assessment : Probability or evidence of skin sensitisation in humans

Result : positive

Starch:

Test Type : Maximisation Test

Losartan Formulation



Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.0 06.04.2024 19366-00023 Date of first issue: 07.10.2014

Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Losartan:

Genotoxicity in vitro : Test Type: in vitro assay

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster ovary cells

Result: negative

Test Type: Alkaline elution assay

Result: negative

Test Type: Chromosomal aberration

Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration

Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Cellulose:

Species : Rat

Losartan Formulation



Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.0 06.04.2024 19366-00023 Date of first issue: 07.10.2014

Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Losartan:

Species : Mouse
Application Route : Oral
Exposure time : 92 weeks

Dose : 200 mg/kg body weight

Result : negative

Species : Rat Application Route : Oral

Exposure time : 105 weeks

Dose : 270 mg/kg body weight

Result : negative

Reproductive toxicity

May damage the unborn child.

May cause harm to breast-fed children.

Components:

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Losartan:

Effects on fertility : Test Type: Fertility

Species: Rat, female Application Route: Oral

Fertility: LOAEL: 200 mg/kg body weight Result: female reproductive effects Remarks: Maternal toxicity observed.

Effects on foetal develop-

ment

: Test Type: Development

Species: Rabbit Application Route: Oral

General Toxicity Maternal: NOAEL: 10 mg/kg body weight Developmental Toxicity: NOAEL F1: 20 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, No

teratogenic effects





Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.0 06.04.2024 19366-00023 Date of first issue: 07.10.2014

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 10 mg/kg body weight

Result: Fetotoxicity, No teratogenic effects

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

Studies indicating a hazard to babies during the lactation peri-

od

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

Components:

Losartan:

Exposure routes : Ingestion

Target Organs : Blood, Cardio-vascular system, Stomach, Kidney

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg

Application Route : Ingestion Exposure time : 90 Days

Losartan:

Species : Rat
LOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 309 d
Number of exposures : daily

Target Organs : Blood, Kidney, Cardio-vascular system, Stomach

Species : Dog
NOAEL : 5 mg/kg
Application Route : Oral
Exposure time : 1 Months

Symptoms : Salivation, Vomiting



Losartan Formulation

- ⇔ ORGANON

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.0 06.04.2024 19366-00023 Date of first issue: 07.10.2014

Species : Dog
LOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 53 Weeks
Number of exposures : daily

Symptoms : Salivation, Vomiting

Starch:

Species : Rat

NOAEL : >= 2,000 mg/kg
Application Route : Skin contact
Exposure time : 28 Days

Method : OECD Test Guideline 410

Aspiration toxicity

Not classified based on available information.

Components:

Losartan:

No aspiration toxicity classification

Experience with human exposure

Components:

Losartan:

Eye contact : Symptoms: Eye irritation

Ingestion : Symptoms: hypotension, tachycardia

Section 12: Ecological information

Toxicity

Components:

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Losartan:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 929 mg/l

Exposure time: 96 h Method: FDA 4.11

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 331 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Losartan Formulation



Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.0 06.04.2024 19366-00023 Date of first issue: 07.10.2014

Toxicity to algae/aquatic : NOEC (Microcystis aeruginosa (blue-green algae)): 949 mg/l

plants Exposure time: 10 d Method: FDA 4.01

NOEC (Selenastrum capricornutum (green algae)): 143 mg/l

Exposure time: 10 d Method: FDA 4.01

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 10 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 100 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Losartan:

Stability in water : Hydrolysis: < 10 %(5 d)

Bioaccumulative potential

Components:

Losartan:

octanol/water

Partition coefficient: n-

•

log Pow: 1.2

Mobility in soil

No data available

Other adverse effects

No data available

Section 13: Disposal considerations

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

Losartan Formulation



Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.0 06.04.2024 19366-00023 Date of first issue: 07.10.2014

Section 14: Transport information

International Regulations

UNRTDG

UN number : Not applicable
UN proper shipping name : Not applicable
Transport hazard class(es) : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
UN proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo : Not applicable

aircraft)

Packing instruction (passen- : Not applicable

ger aircraft)

IMDG-Code

UN number Not applicable Not applicable UN proper shipping name Not applicable Class Subsidiary risk Not applicable Not applicable Packing group Not applicable Labels **EmS Code** Not applicable Marine pollutant Not applicable

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

Section 15: Regulatory information

Safety, health and environmental regulations specific for the product in question

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Not applicable

Environmental Protection and Management Act and

Environmental Protection and Management (Hazard-

ous Substances) Regulations

Fire Safety (Petroleum and Flammable Materials) : Not applicable

Losartan Formulation



Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.0 06.04.2024 19366-00023 Date of first issue: 07.10.2014

Regulations

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Section 16: Other information

Revision Date : 06.04.2024

Further information

Sources of key data used to

compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

SG OEL : Singapore. Workplace Safety and Health (General Provisions)

Regulations - First Schedule Permissible Exposure Limits of

Toxic Substances.

ACGIH / TWA : 8-hour, time-weighted average

SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant: DIN - Standard of the German Institute for Standardisation: DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods: IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New

Losartan Formulation



Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.0 06.04.2024 19366-00023 Date of first issue: 07.10.2014

Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN